U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06898255) titled 'A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients with Pre-cachexia or Cachexia' on March 14.
Brief Summary: An open-label, multi-center, phase I study to evaluate the safety/tolerability and pharmacokinetics of GFS202A in advanced solid tumor patients with pre-cachexia or cachexia. The primary objective is to assess the safety/tolerability of GFS202A, determine its maximum tolerated dose (MTD), and recommend a dose range for future studies.
Enroll participants with cancer cachexia or precachexia to receive GFS202A monotherapy. During the study period, participants will undergo assessments for safety and prelimi...